Pro Dex INC 8-K filings

Pro-Dex, Inc. has published an updated investor presentation to be utilized for analyst and investor communications throughout the remainder of 2026.

Pro-Dex, Inc. achieved record quarterly revenue of $19.9 million for Q3 2026, driven by strong orthopedic handpiece shipments.

Pro-Dex, Inc. announced a base salary increase for its Chief Financial Officer, Alisha K. Charlton, to $257,000 per year.

Pro-Dex, Inc. completed the acquisition of Advanced Precision Machining LLC for $8.65 million, funded by cash and a new $6.65 million term loan, extending its manufacturing capabilities and market reach.

Pro-Dex, Inc. announced robust financial results for its fiscal 2026 second quarter and six months, driven by increased sales of its next-generation orthopedic handpiece and strategic customer contract extensions.

Pro-Dex, Inc. announced a three-year contract extension with its largest customer, ensuring continued revenue, alongside a $225,000 bonus for CEO Richard L. Van Kirk.

Pro-Dex, Inc. announced restricted share grants, a cash bonus for its CEO, and the results of its 2025 Annual Meeting of Shareholders, including director elections and plan amendments.

Pro-Dex, Inc. announced a 24% increase in net sales to $18.5 million and a significant rise in net income to $4.7 million for its fiscal 2026 first quarter, driven by next-generation handpiece shipments and investment gains.

Pro-Dex, Inc. announced significant revenue and operating income growth for fiscal year 2025, despite a decrease in gross margin and net income for the fourth quarter.

PRO-DEX, Inc. announced discretionary cash bonuses for its CEO and CFO, citing strong fiscal 2025 financial performance and sales growth.

Pro-Dex, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP due to a merger.

Pro-Dex, Inc. announces a significant increase in net sales and net income for Q3 2025, driven by strong demand for its next-generation orthopedic handpiece.

Pro-Dex, Inc. has increased its revolving line of credit to $11 million through an amendment to its credit agreement with UMB Bank, providing enhanced financial resources.

Pro-Dex, Inc. reports a significant increase in net sales and profitability for the second quarter of fiscal year 2025, driven by strong demand for its next-generation orthopedic handpiece.

Pro-Dex, Inc. has amended its credit agreement with Minnesota Bank & Trust, extending the maturity date of its $7 million revolving line of credit to December 29, 2026.

Pro-Dex, Inc. has granted restricted stock awards to its non-employee directors and select employees, including the CEO and CFO, which will vest over five years.

Pro-Dex, Inc. held its 2024 Annual Meeting of Shareholders, where shareholders voted on the election of directors, ratification of the accounting firm, and executive compensation.

Pro-Dex, Inc. announced a significant increase in net sales and profitability for the first quarter of fiscal year 2025, driven by strong demand and a favorable product mix.

Pro-Dex, Inc.'s Compensation Committee approved a $70,000 bonus for CEO Richard L. Van Kirk based on the company's performance in the first quarter of fiscal year 2025.

Pro-Dex, Inc. announced a significant increase in net sales for both the fourth quarter and full fiscal year 2024, primarily driven by increased demand from their largest customer.

Pro-Dex, Inc. has awarded discretionary bonuses to its CEO and CFO following the company's sales growth and fiscal 2024 financial performance exceeding expectations.

Pro-Dex, Inc. has entered into an agreement for a $5 million term loan to refinance existing debt and support its stock repurchase program.

Pro-Dex, Inc. announced a 9% increase in net sales for the third quarter of fiscal year 2024, but net income was significantly impacted by unrealized losses on marketable equity investments.

Pro-Dex, Inc. announced a 12% increase in net sales for the second quarter of fiscal year 2024, but experienced a decrease in net income due to higher operating expenses and unrealized losses on marketable equity investments.